The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

Both benign and malignant prostate diseases elevate total prostate-specific antigen (tPSA), and the incidence of benign disease increases markedly with age. There is evidence, however, that free-to-total PSA ratio (%fPSA) and human kallikrein 2 (hK2) more closely reflect the malignant process. We te...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Vickers, A, Ulmert, D, Serio, A, Björk, T, Scardino, P, Eastham, J, Berglund, G, Lilja, H
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2007

Eitemau Tebyg

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
gan: Ulmert, D, et al.
Cyhoeddwyd: (2008)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
gan: Ulmert, D, et al.
Cyhoeddwyd: (2008)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
gan: Lilja, H, et al.
Cyhoeddwyd: (2007)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study
gan: Berglund Göran, et al.
Cyhoeddwyd: (2008-02-01)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
gan: Vickers, A, et al.
Cyhoeddwyd: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
gan: Vickers, A, et al.
Cyhoeddwyd: (2010)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
gan: Carlsson, S, et al.
Cyhoeddwyd: (2012)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
gan: Lilja, H, et al.
Cyhoeddwyd: (2011)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
gan: Lilja, H, et al.
Cyhoeddwyd: (2008)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
gan: Lilja, H, et al.
Cyhoeddwyd: (2008)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
gan: Savage, C, et al.
Cyhoeddwyd: (2010)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
gan: Steuber, T, et al.
Cyhoeddwyd: (2007)

Screening for prostate cancer: an update.
gan: Shariat, S, et al.
Cyhoeddwyd: (2008)

Five genetic variants associated with prostate cancer.
gan: Vickers, A, et al.
Cyhoeddwyd: (2008)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
gan: Vickers, A, et al.
Cyhoeddwyd: (2011)

Prostate cancer: estimating the benefits of PSA screening.
gan: Vickers, A, et al.
Cyhoeddwyd: (2009)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
gan: Ulmert, D, et al.
Cyhoeddwyd: (2009)

Screening for prostate cancer.
gan: Carlsson, S, et al.
Cyhoeddwyd: (2012)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
gan: Steuber, T, et al.
Cyhoeddwyd: (2007)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
gan: Ulmert, D, et al.
Cyhoeddwyd: (2006)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
gan: Vickers, A, et al.
Cyhoeddwyd: (2010)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
gan: Vickers, A, et al.
Cyhoeddwyd: (2010)

Screening for prostate cancer: To the editor
gan: Carlsson, S, et al.
Cyhoeddwyd: (2012)

Urological cancer: Time for another rethink on prostate cancer screening.
gan: Vickers, A, et al.
Cyhoeddwyd: (2012)

Screening for prostate cancer: early detection or overdetection?
gan: Vickers, A, et al.
Cyhoeddwyd: (2012)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
gan: Klein, R, et al.
Cyhoeddwyd: (2012)

Predicting prostate cancer many years before diagnosis: how and why?
gan: Vickers, A, et al.
Cyhoeddwyd: (2012)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
gan: Gupta, A, et al.
Cyhoeddwyd: (2010)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
gan: Vickers, A, et al.
Cyhoeddwyd: (2008)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
gan: Vickers, A, et al.
Cyhoeddwyd: (2010)

Prostate cancer screening
gan: James Eastham
Cyhoeddwyd: (2017-07-01)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
gan: Wenske, S, et al.
Cyhoeddwyd: (2009)

Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.
gan: Stephenson, A, et al.
Cyhoeddwyd: (2006)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
gan: Michael Tzeng, et al.
Cyhoeddwyd: (2021-08-01)

Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer.
gan: Lilja, H, et al.
Cyhoeddwyd: (2007)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
gan: O'Brien, M, et al.
Cyhoeddwyd: (2009)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
gan: Scardino Peter T, et al.
Cyhoeddwyd: (2008-07-01)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
gan: Steuber, T, et al.
Cyhoeddwyd: (2006)

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
gan: Klein, R, et al.
Cyhoeddwyd: (2010)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
gan: Christensson, A, et al.
Cyhoeddwyd: (2011)